Fig. 5: Progression-free survival (PFS) by pS6 status and histological subtype. | Modern Pathology

Fig. 5: Progression-free survival (PFS) by pS6 status and histological subtype.

From: Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project

Fig. 5

A PFS by pS6 status; epithelioid patients. B PFS by pS6 status; non-epithelioid patients. Interaction p-value (from Cox model including pS6 status with histology interaction): <0.001. Overall median PFS was 14.3 months (95% CI: 12.4–15.9) for epithelioid patients and 8.8 months (95% CI: 6.3–10.4) for non-epithelioid. Log-rank p-value comparing pS6 high vs. low: 0.18 for epithelioid; <0.001 for non-epithelioid.

Back to article page